Do the SCORE2 and SCORE2-OP risk models accurately predict cardiovascular risk and provide clinical utility in a UK population cohort?
While the SCORE2 model is useful for preventive treatment decisions in the general UK population, the SCORE2-OP model performs poorly and underestimates risk in older adults (70-79 years).
In a UK population cohort, the SCORE2 low-risk model showed fair discrimination and calibration, with clinical benefit for preventive treatment initiation decisions. In contrast, in individuals aged 70-79 years, SCORE2-OP demonstrated poor discrimination, underestimated risk in both sexes, and limited clinical utility.
Trier et al. (Wed,) studied this question.